Education and Training
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is the good cholesterol helping to protect against heart disease. Currently one known treatment for this a medication called fenofibrate, another medication that can improve insulin resistance is rosiglitazone, a third treatment known to improve insulin resistance an decrease triglycerides is weight loss. In this study insulin resistant individuals with elevated triglycerides and or a ratio of triglycerides to HDL cholesterol of 3:1 or greater will be randomized (selected by chance) to receive one of these treatments and results of insulin sensitivity and cardiac risk profiles will be compared at the end of the study.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Rosiglitazone
- drug: Fenofibrate
- behavioral: Weight Loss
Eligibility
Inclusion Criteria:
Insulin Resistant Triglyceride 150 mg/dL or greater or triglyceride HDL-C ratio 3 or
greater BMI 25-35
Exclusion Criteria:
Diabetes Mellitus History of gall stones History of CHF History of CAD Severe
anemia,kidney, or liver disease
Ages Eligible for Study
30 Years - 65 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting